Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
University of Alabama at Birmingham
University of Alabama at Birmingham
Baptist Health South Florida
University of Florida
Pfizer
Mayo Clinic
Thomas Jefferson University
Institut du Cancer de Montpellier - Val d'Aurelle
Blueprint Medicines Corporation
Bexion Pharmaceuticals, Inc.
ABM Therapeutics Corporation
EpicentRx, Inc.
University of Utah
Stanford University
Basilea Pharmaceutica
Pyramid Biosciences
Providence Health & Services
University of Florida
Stanford University
Bexion Pharmaceuticals, Inc.
Tocagen Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
University of Pittsburgh
Duke University
Masonic Cancer Center, University of Minnesota
University of Cincinnati
Brain & Spine Surgeons of New York
University of Virginia
OHSU Knight Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Washington
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University Health Network, Toronto
Life Molecular Imaging SA
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Duke University
SWOG Cancer Research Network
Copenhagen University Hospital at Herlev
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
UNC Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Diffusion Pharmaceuticals Inc
Case Comprehensive Cancer Center